BACKGROUND Antiretroviral therapy (ART) has dramatically reduced mortality among HIV-positive individuals and has been associated with declining HIV incidence. [1] [2] [3] Numerous guidelines now recommend ART for all HIV-positive individuals, irrespective of CD4 counts. [4] [5] [6] These approaches are supported by randomized trials demonstrating the benefits of early ART on improved clinical outcomes for HIVpositive individuals, 7 as well as reductions in onward transmission. 8 However, concerns remain that changes in HIV risk behavior could undermine "treatment as prevention" (TasP) effectiveness. Previous research studies have found associations between HIV sexual risk behavior and positive attitudes toward ART's preventive value, 9 particularly among men who have sex with men (MSM). 10, 11 Most of this research pre-dates any formal adoption of TasP as policy, but relied on knowledge acquired from peers or health care providers.
Several jurisdictions have recently adopted and are actively promoting TasP. [12] [13] [14] In British Columbia (BC), Canada, TasP was introduced in 2010 through a pilot project in Vancouver and expanded province wide in 2012. 15 Thus, MSM in Vancouver have been exposed to TasP messages for several years through clinicians, the media, and likely discussions with peers and community leaders. 16 A previous crosssectional analysis from our group demonstrated that indeed, higher HIV treatment optimism was associated with risky sex and that HIV-positive MSM had much higher HIV treatment optimism scores than those of HIV-negative/ unknown MSM. 17 To explore temporal changes in these relationships, we used data from the prospective cohort of the same study of Vancouver-based MSM to examine trends in attitudes regarding the benefits of ART and risky sex over a 3-year period, whereas TasP policy was actively implemented across BC.
METHODS
We enrolled sexually active MSM aged $16 years in a longitudinal study from February 2012 to February 2015, using respondent-driven sampling as a recruitment strategy. 18 Enrollment of HIV-negative participants concluded in February 2014, but we continued to enroll HIV-positive participants for an additional year. Seed participants were recruited through community contacts, mobile phone applications, and websites catering to Vancouver-based MSM. 19 After providing informed consent, participants completed a selfadministered computer-based survey and nurse-administered clinical questionnaire. We collected sexual risk and drug using behaviors using a 6-month recall timeframe. The survey included the HIV treatment Optimism-Skepticism Scale (HOSS), a 12-item validated instrument for measuring attitudes toward HIV and ART. 20 Higher HOSS scores indicate increased agreement with benefits of ART. Participants completed follow-up visits every 6 months using a modified version of the enrollment questionnaire. This analysis included data collected until August 31, 2015. The study received approval from the University of British Columbia, Simon Fraser University, and the University of Victoria.
We performed descriptive statistics and bivariate analyses of data collected at enrollment, using Wilcoxon rank-sum and x 2 tests. We examined trends in HOSS scores, the proportions of participants reporting risky sex [defined as condomless anal sex (CAS) with a serodiscordant/ unknown serostatus partner in the previous 6 months], and the proportions agreeing or strongly agreeing with a statement in the HOSS known as the TasP statement ("a person with an undetectable viral load cannot pass on the virus") in each 6-month period using univariable generalized mixed-effect modeling. In these analyses, calendar time was used as a covariate. We used mixed-effects modeling to examine associations with risky sex and time, with separate models using the full HOSS scores or only TasP statement responses forced into separate models. Final models were determined using backward selection method, where variables with the highest type-III P value at each step were excluded until Akaike Information Criterion was minimized. All variables included in final models were checked for collinearity and interactions. All analyses were stratified based on selfreported HIV status and conducted using SAS (version 9.4; SAS Corporation Cary, NC).
RESULTS
We enrolled 774 participants in the cross-sectional survey; 556 (71.8%) self-reported as HIV negative/unknown and 218 (28.2%) as HIV positive. Of these, 181 (83.0%) were receiving ART at enrollment and 167 (92.3% of those on ART) had a VL ,200 copies/mL. None of the HIV-negative participants were receiving pre-exposure prophylaxis (PrEP) at enrollment, and only 8 reported using it by the end of follow-up. The median age was 34 years; 585 (75.6%) were identified as white, 74 (9.6%) Asian, 50 (6.5%) Aboriginal, 35 (4.5%) Latino, and 30 (3.9%) other. A total of 655 (85.6%) were identified as gay, 73 (9.4%) as bisexual, and 46 (5.9%) as other sexual orientations.
Compared with HIV-negative/ unknown participants, HIV-positive participants were more likely to be .40 years (74.5% vs. 21.6%; P , 0.001) and white (78.4% vs. 74.5%; P = 0.019) and report an income of $$30,000 CAD (28.0% vs. 41.0%; P = 0.001). HIVpositive participants reported more anal sex partners in the previous 6 months (median 4 vs. 3; P , 0.001), were less likely to report always using condoms during anal sex (33.5% vs. 64.0%; P , 0.001), and were more likely to report any risky sex (46.5% vs. 35.4%; P = 0.005). HIV-positive men had higher HOSS scores (median 28 vs. 24; P , 0.001) and were more likely to have heard of TasP (73.3% vs. 43.1%, P , 0.001) and to agree with the TasP statement (45.4% vs. 22.8%; P , 0.001).
A total of 698 participants (90.2%) agreed to participate in the cohort study and 575 (82.4%) completed at least 1 follow-up visit. The median follow-up time was 1.98 years. Among HIVpositive participants, median HOSS scores increased over time (Fig. 1A) , from 28 (Q1-Q3: 26-32) in JulyDecember 2012 to 31 (Q1-Q3: 27-35) in January-June 2015 (test of trend P , 0.001). From periods 1-6, the proportions of HIV-positive participants agreeing with the TasP statement and reporting risky sex increased nonsignificantly from 46% to 55% (P = 0.111) and from 29% to 41% (P = 0.656), respectively. Among HIV-negative/ unknown participants, HOSS scores also increased (Fig. 1B) , from 24 (Q1-Q3: 20-26) to 26 (Q1-Q3: 24-29) in periods 1-6 (P , 0.001), as did TasP statement agreement (20%-36%, periods 1-6; P , 0.001). However, proportions of HIVnegative men reporting risky sex were unchanged (30% in period 1 and 27% in period 6; P = 0.104).
In 
DISCUSSION
We observed increasing awareness regarding the preventive value of ART among HIV-negative MSM and increases in HOSS scores among both HIV-negative and HIV-positive MSM prospectively followed from July 2012 to June 2015 in Vancouver. These attitude changes occurred over a period when TasP was actively promoted by the BC Ministry of Health. However, we did not observe proportional changes in MSM reporting risky sex over the same period for either HIV-negative or HIVpositive men, suggesting that TasP promotion in BC is not undermining other HIV prevention measures, such as condom promotion.
The TasP agreement was low (20%) among HIV-negative/unknown participants in 2012, but reached 43% by the second half of 2015, suggesting that diffusion of this knowledge among HIVnegative MSM is approaching that of HIV-positive MSM (54% in last period). This level of TasP agreement among HIVpositive MSM is similar to that recently reported in Australia (46.2%), using a slightly different TasP knowledge assessment, 21 but much higher than was reported for HIV-negative MSM (10.0%).
This study has a number of limitations. First, CAS with a serodiscordant/unknown serostatus partner may not be an accurate measure of risk behavior, given the increasing availability of PrEP for MSM in industrialized countries and that virologically suppressed HIVpositive individuals are very unlikely to transmit HIV. 22 However, we have found that CAS with a known HIVpositive partner is associated with a greater incident HIV risk. 23 Furthermore, there was no PrEP use reported at enrollment, 24 and only 8 participants reported any use during follow-up, 25 suggesting validity of this measure of risky sex in our setting. Second, our primary outcome measure of risky sex over a 6-month period did not include a frequency component. Last, individuals retained in the cohort may differ from those lost to follow-up, potentially affecting trends we did or did not observe.
In conclusion, we found proportional increases of HIV-positive and HIV-negative MSM in Vancouver reporting agreement with the preventive benefit of ART over time, during a timeframe when TasP policy was actively implemented. We found no proportional changes of MSM reporting sexual acts putting them at risk of transmitting or acquiring HIV during the same period. This study offers some reassurance that risk compensation may not inevitably occur as TasP is promoted. BACKGROUND Suboptimal adherence to either HIV therapy or pre-exposure prophylaxis (PrEP) increases the risk of virologic failure, drug resistance, and HIV transmission or acquisition. [1] [2] [3] Hair concentrations of antiretrovirals (ARVs), which reflect cumulative exposure over weeks to months, are more strongly predictive of virologic response than self-reported adherence in HIV treatment [4] [5] [6] and predict toxicities 7 and dosing patterns 8 among individuals on PrEP.
Measuring hair concentrations of ARVs to estimate adherence and exposure has several advantages, including lower susceptibility to "white coat adherence" patterns 9 and the ability to estimate long-term adherence. 10 Hair samples are collected noninvasively, do not require sterile equipment, and can be stored and shipped at room temperature and without biohazardous precautions.
In studies examining hair concentrations of ARVs to date, trained staff have collected hair samples from the back of participants' heads. However, just as self-collection of genital swabs can facilitate testing for sexually transmitted infections, 11 home collection of hair samples may increase recruitment and retention in research because of reduced travel time and expense. In addition, because hair is more readily self-sampled from the side of the head, confirming ARV concentrations are similar across the scalp would bolster the case for home collection.
We conducted a pilot study to (1) evaluate the feasibility and acceptability of home collection of hair samples and (2) examine the correlation and agreement between ARV levels in hair collected at a study site by staff and hair collected at home by participants, as well as the correlation and agreement between ARV levels in hair collected from the back versus the side of the head.
METHODS

Participants and Sample Collection
We recruited participants $18 years of age on tenofovir (TFV) disoproxil fumarate (TDF)/emtricitabine (FTC)-containing ARV regimens for at least 3 months. TDF/FTC is the backbone for ARV regimens and the combination used for PrEP and has the most comprehensive data on dose-hair concentration relationships. 8 Participants with renal insufficiency were excluded.
Individuals who met study criteria were emailed a video link (http://rxpix. ucsf.edu/study-archives) describing the overall study objectives and demonstrating home collection of hair. Consenting participants attended study visits at University of California, San Francisco (UCSF), at baseline, 6, and 12 weeks. Trained staff collected hair samples from the back and side of participants' heads, at these 3 time points. At 6 and 12 weeks, we mailed the participants hair collection kits that included detailed instructions for home collection of hair (http://rxpix.ucsf.edu/study-archives), supplies for hair sample collection, and a prestamped addressed envelope to mail the hair samples back to study staff. Participants were instructed to collect hair samples from the back and side of their heads and ask for assistance from a friend or family member if desired. The study protocol was approved by the UCSF Institutional Review Board.
Laboratory Methods
The UCSF Hair Analytical Laboratory (HAL) has developed, validated, and reported on methods to analyze TFV, FTC, and other ARVs in small hair samples using liquid chromatography/tandem mass spectrometry. 5, 10, 12, 13 The laboratory's hair assays for TFV and FTC have been peer reviewed and approved by the Division of AIDS Clinical Pharmacology and Quality Assurance program. 14 Detailed methods for hair analyses have been previously described. 8 
Data Analysis
Feasibility of home collection of hair samples was defined as the proportion of participants who mailed back adequate hair samples to the study site. Acceptability of home collection was evaluated through qualitative exit interviews focused on participants' opinions on home collection of hair samples.
Qualitative Data
The first and third authors identified themes from exit interview and 
